For decades, cancer researchers faced a frustrating paradox. They knew that mutations in the RAS family of genes were helping drive some of the world’s most difficult cancers, yet knowing the culprit did not mean they could successfully target it.
RAS became one of oncology’s most notorious challenges.
In 2026, that story changed significantly.
A drug called daraxonrasib, marketed in the United States as Rasonque, received FDA approval for certain adults with metastatic pancreatic adenocarcinoma after a phase 3 trial showed substantially longer median survival than standard chemotherapy.
Then another intriguing result emerged. In an early-stage clinical trial, the same drug produced measurable tumor responses in some patients with advanced non-small-cell lung cancer carrying RAS mutations.
The two findings do not mean scientists have discovered a universal cancer drug. Daraxonrasib is not currently FDA-approved for lung cancer, and important questions about its effectiveness and safety remain.
But the broader story may ultimately prove more consequential: researchers are learning how to interfere with a molecular pathway that once seemed extraordinarily difficult to drug.
Cancer Can Be Defined by More Than the Organ Where It Begins
We commonly describe cancers according to anatomy: pancreatic cancer, lung cancer, breast cancer or colorectal cancer.
That classification remains essential, but modern oncology increasingly adds another question:
What molecular changes are helping this particular tumor survive and grow?
This distinction matters because tumors arising in different organs can sometimes share important molecular vulnerabilities. Conversely, two cancers developing in the same organ may carry very different genetic alterations and respond differently to treatment.
RAS provides a particularly striking example.
RAS proteins are part of a cellular signaling network involved in controlling growth and division. In simplified terms, they behave somewhat like molecular switches, moving between active and inactive states.
Cancer-associated mutations can disrupt that regulation, allowing growth-promoting signals to remain active when they should be switched off.
The connection is especially strong in pancreatic ductal adenocarcinoma, where more than 90% of tumors harbor oncogenic RAS mutations.
That would seem to make RAS an obvious target.
For years, however, obvious did not mean achievable.
Why RAS Became One of Oncology’s Toughest Targets
Researchers have understood the importance of RAS in cancer for decades. The difficulty was finding drugs capable of interfering with these proteins effectively and selectively.
The biochemical characteristics of RAS made conventional drug development unusually challenging, and the target acquired a reputation for being effectively “undruggable.”
That view has gradually changed.
The development of inhibitors against specific KRAS mutations proved that at least some forms of the protein could be targeted pharmacologically. But RAS-driven cancers are molecularly diverse, and targeting a single mutation leaves many others untouched.
Daraxonrasib takes a broader approach.
It is an oral multi-selective RAS(ON) inhibitor, designed to interfere with multiple oncogenic RAS proteins in their active state rather than targeting only one narrowly defined mutation.
The approach has now faced an important real-world test in metastatic pancreatic cancer.
The Pancreatic Cancer Trial That Changed the Drug’s Status
The phase 3 RASolute 302 trial enrolled 500 patients with metastatic pancreatic adenocarcinoma whose disease had progressed following previous systemic treatment.
Participants were randomly assigned to receive either daraxonrasib or an investigator-selected standard chemotherapy regimen.
The survival results were striking.
Median overall survival reached 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy.
Median progression-free survival was 7.2 months versus 3.6 months, while the objective response rate was approximately 30% with daraxonrasib compared with 11% with chemotherapy.
These figures require careful interpretation.
A median overall survival of 13.2 months does not mean that everyone taking the drug lives for exactly that length of time. Nor does comparing 13.2 with 6.7 months mean every patient automatically gains an additional 6.5 months.
A median identifies the point at which half of the patients in a group have experienced the measured event. Individual outcomes can vary considerably.
Nevertheless, the difference between the treatment groups was clinically meaningful enough to contribute to a major regulatory decision.
Rasonque Received FDA Approval in August 2026
On August 26, 2026, the FDA approved daraxonrasib under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.
That wording matters.
Rasonque is not automatically appropriate for everyone diagnosed with pancreatic cancer, and its approval does not mean existing treatments have suddenly become obsolete.
It provides another therapeutic option for a specifically defined patient population.
According to the prescribing information, the recommended dose is 300 mg orally once daily, continued until disease progression or unacceptable toxicity.
The pancreatic cancer results alone would make daraxonrasib noteworthy.
But another question quickly became relevant: if the drug targets active RAS signaling rather than simply the organ where a tumor originated, could it also work against RAS-driven cancers elsewhere in the body?
Lung cancer provided an early opportunity to investigate that possibility.
What Researchers Found in RAS-Mutated Lung Cancer
A phase 1–2 study published in the New England Journal of Medicine investigated daraxonrasib in previously treated patients with advanced RAS-mutated non-small-cell lung cancer (NSCLC).
This qualification is essential.
The study was not testing the drug against every form of lung cancer.
RAS-family mutations occur in approximately 30% of patients with NSCLC, according to the study authors.
The safety and efficacy analysis included 136 patients treated with doses of up to 300 mg per day.
The primary purpose of this early-stage trial was to investigate safety, but researchers also measured antitumor activity.
They found something worth pursuing.
Tumors Responded in More Than 30% of Patients
The objective response rate was 31% among patients receiving doses of up to 120 mg, 34% among those receiving 160–220 mg, and 37% among patients receiving 300 mg.
Those percentages can easily become misleading when translated into headlines.
An “objective response” does not mean the patient was cured.
It means that the cancer shrank sufficiently to meet standardized criteria for a complete or partial response. Some patients can therefore experience a meaningful tumor reduction without their cancer disappearing entirely.
For people with advanced, previously treated disease, seeing this degree of antitumor activity is scientifically significant.
But it is not the same level of evidence that exists for pancreatic cancer.
Why This Is Not Yet a Lung Cancer Treatment
The contrast between the two studies illustrates something important about how new cancer therapies reach patients.
For metastatic pancreatic cancer, researchers have completed a randomized phase 3 trial involving 500 patients, directly compared daraxonrasib with established chemotherapy options, demonstrated a survival benefit and subsequently obtained FDA approval.
The lung cancer evidence comes from a phase 1–2 trial, where safety was the primary endpoint.
That is a much earlier point in clinical development.
The results provide a strong reason to continue investigating daraxonrasib in RAS-mutated NSCLC. They do not establish the drug as an approved lung cancer therapy.
So a headline saying that a pancreatic cancer drug is showing promise in certain RAS-mutated lung cancers is defensible.
Saying that scientists now have a drug approved to treat both pancreatic and lung cancer would not be.
The Safety Data Matter Too
Tumor shrinkage is only one side of the equation when researchers evaluate a cancer treatment.
In the lung cancer study, almost every participant experienced at least one adverse event, regardless of whether investigators considered it related to daraxonrasib, and 54% experienced an adverse event of grade 3 or higher.
Common problems included rash, diarrhea, nausea, vomiting and inflammation affecting the mouth.
The official Rasonque prescribing information also includes warnings concerning potentially serious dermatologic and soft-tissue toxicity, oral disorders, diarrhea, gastrointestinal perforation and interstitial lung disease/pneumonitis.
This does not negate the drug’s potential benefits. Cancer treatment routinely involves balancing therapeutic benefit against toxicity.
It does explain why early response rates alone cannot determine whether an experimental therapy should become standard treatment.
Researchers need to understand not only whether a drug works, but how long its benefits last, which patients benefit most and what risks accompany those benefits.
What We Know — and What We Still Don’t
At this point, the evidence tells two different but complementary stories.
We know that daraxonrasib improved median overall and progression-free survival compared with chemotherapy in a randomized phase 3 trial involving patients with previously treated metastatic pancreatic adenocarcinoma. The FDA subsequently approved the drug for a defined pancreatic cancer population.
We also know that daraxonrasib demonstrated antitumor activity in an early clinical study involving patients with previously treated, advanced RAS-mutated NSCLC.
What we do not yet know is whether the lung cancer results will translate into the kind of survival benefit that can be demonstrated in larger randomized trials, how the treatment will compare with existing options, or precisely which molecular subgroups will derive the greatest benefit.
That distinction between promising evidence and established clinical benefit is crucial whenever early cancer research reaches social media.
The Bigger Story Is Precision Oncology
There is another reason daraxonrasib deserves attention.
Its development illustrates a fundamental change in how cancer is increasingly understood.
A tumor’s location still matters enormously. But its molecular characteristics can reveal vulnerabilities that anatomy alone cannot.
A pancreatic tumor and a lung tumor are clearly not the same disease. Yet if both rely on related RAS signaling mechanisms, researchers can investigate whether disrupting that pathway has therapeutic value in both.
This is one of the central ideas behind precision oncology.
Instead of asking only:
“Where did the cancer originate?”
researchers increasingly also ask:
“What is driving this particular tumor?”
The answer can influence which treatments are worth testing.
A Breakthrough Doesn’t Have to Be a Cure
Cancer research is particularly vulnerable to two opposite distortions.
One turns every encouraging study into a “cancer cure.”
The other dismisses anything short of a cure as insignificant.
Neither reflects how medical progress usually happens.
Cancer is not one disease, and tumors can evolve, develop resistance and behave very differently from one patient to another. Progress therefore tends to arrive incrementally: researchers identify a molecular abnormality, learn how it functions, develop a compound capable of interfering with it, test that compound in small studies and eventually determine through larger trials whether patients actually live longer or experience better outcomes.
Daraxonrasib has already traveled a substantial part of that path in metastatic pancreatic cancer.
In RAS-mutated lung cancer, it is much earlier in the journey.
From “Almost Impossible to Drug” to a Treatment Patients Can Actually Receive
Rasonque is not a universal cancer treatment. It does not work for everyone, it can cause significant adverse effects, and it is not currently FDA-approved for lung cancer.
None of those facts make the development unimportant.
In metastatic pancreatic adenocarcinoma, median overall survival in a phase 3 trial was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy.
In previously treated RAS-mutated NSCLC, an early clinical trial found objective responses in more than 30% of evaluated patients.
The next question is therefore not whether scientists have suddenly “cured cancer.”
It is whether a therapeutic strategy that has already produced meaningful results in one notoriously difficult disease can be extended to other tumors driven by similar molecular machinery.
For decades, RAS represented an obvious target that researchers struggled to reach.
Now, at least in some clinical settings, they can reach it.
And that may be the most important part of the story.
Sources
This article is based primarily on regulatory information and peer-reviewed clinical research. The key references are the FDA announcement of the Rasonque approval, the phase 3 RASolute 302 pancreatic cancer study published in The New England Journal of Medicine, the phase 1–2 study of daraxonrasib in RAS-mutated non-small-cell lung cancer and the official FDA prescribing information for Rasonque.